Drugs / VGN-R13
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06849609 | Jan 2025 → May 2026 overdue | amyotrophic lateral sclerosis | Hong Chen | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VGN-R13 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06849609 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “An adeno-associated viral vector 9 gene therapy product.” NCT06849609 ↗ |
| Route | Intrathecal | “through intrathecal injection” NCT06849609 ↗ |